<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27653566</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>12</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1533-4406</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>375</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Sep</Month>
              <Day>22</Day>
            </PubDate>
          </JournalIssue>
          <Title>The New England journal of medicine</Title>
          <ISOAbbreviation>N Engl J Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Primary Sclerosing Cholangitis.</ArticleTitle>
        <Pagination>
          <StartPage>1161</StartPage>
          <EndPage>1170</EndPage>
          <MedlinePgn>1161-70</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMra1506330</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lazaridis</LastName>
            <ForeName>Konstantinos N</ForeName>
            <Initials>KN</Initials>
            <AffiliationInfo>
              <Affiliation>From the Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>LaRusso</LastName>
            <ForeName>Nicholas F</ForeName>
            <Initials>NF</Initials>
            <AffiliationInfo>
              <Affiliation>From the Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 DK084567</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 DK024031</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 DK057993</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>N Engl J Med</MedlineTA>
        <NlmUniqueID>0255562</NlmUniqueID>
        <ISSNLinking>0028-4793</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>724L30Y2QR</RegistryNumber>
          <NameOfSubstance UI="D014580">Ursodeoxycholic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>N Engl J Med. 2016 Dec 22;375(25):2500-2502</RefSource>
          <PMID Version="1">28002707</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>N Engl J Med. 2016 Dec 22;375(25):2501</RefSource>
          <PMID Version="1">28002708</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>N Engl J Med. ;375(25):2500-01</RefSource>
          <PMID Version="1">28025879</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015209" MajorTopicYN="Y">Cholangitis, Sclerosing</DescriptorName>
          <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058625" MajorTopicYN="N">End Stage Liver Disease</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016031" MajorTopicYN="N">Liver Transplantation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014580" MajorTopicYN="N">Ursodeoxycholic Acid</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>No other potential conflict of interest relevant to this article was reported. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>9</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>9</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27653566</ArticleId>
        <ArticleId IdType="mid">NIHMS885251</ArticleId>
        <ArticleId IdType="pmc">PMC5553912</ArticleId>
        <ArticleId IdType="doi">10.1056/NEJMra1506330</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology. 2013;145:521–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3815445</ArticleId>
            <ArticleId IdType="pubmed">23827861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet. 2013;382:1587–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23810223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lazaridis KN, LaRusso NF. The cholangiopathies. Mayo Clin Proc. 2015;90:791–800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4533104</ArticleId>
            <ArticleId IdType="pubmed">25957621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jussila A, Virta LJ, Pukkala E, Färkkilä MA. Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. Scand J Gastroenterol. 2013;48:1405–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24131389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molodecky NA, Kareemi H, Parab R, et al.  Incidence of primary sclerosing cholangitis: a systematic review and metaanalysis. Hepatology. 2011;53:1590–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21351115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56:1181–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22245904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bambha K, Kim WR, Talwalkar J, et al.  Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125:1364–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14598252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102:1042–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17313496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tischendorf JJ, Hecker H, Krüger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol. 2007;102:107–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17037993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapman R, Fevery J, Kalloo A, et al.  Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20101749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corpechot C, Gaouar F, El Naggar A, et al.  Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology. 2014;146:970–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24389304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eaton JE, Dzyubak B, Venkatesh SK, et al.  Performance of magnetic resonance elastography in primary sclerosing cholangitis. J Gastroenterol Hepatol. 2016;31:1184–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4885758</ArticleId>
            <ArticleId IdType="pubmed">26691631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology. 2002;35:1494–500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12029635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldstein AE, Perrault J, El-Youssif M, Lindor KD, Freese DK, Angulo P. Primary sclerosing cholangitis in children: a longterm follow-up study. Hepatology. 2003;38:210–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12830004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol. 2000;33:537–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11059857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Björnsson E, Olsson R, Bergquist A, et al.  The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008;134:975–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18395078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boonstra K, Weersma RK, van Erpecum KJ, et al.  Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58:2045–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23775876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naess S, Björnsson E, Anmarkrud JA, et al.  Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease. Liver Int. 2014;34:1488–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4128902</ArticleId>
            <ArticleId IdType="pubmed">24517468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendes FD, Jorgensen R, Keach J, et al.  Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101:2070–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16879434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Björnsson E, Chari ST, Smyrk TC, Lindor K. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology. 2007;45:1547–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17538931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stanich PP, Björnsson E, Gossard AA, Enders F, Jorgensen R, Lindor KD. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis. 2011;43:309–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3057302</ArticleId>
            <ArticleId IdType="pubmed">21251891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al Mamari S, Djordjevic J, Halliday JS, Chapman RW. Improvement of serum alkaline phosphatase to &lt;1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2013;58:329–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23085647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rupp C, Rössler A, Halibasic E, et al.  Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Aliment Pharmacol Ther. 2014;40:1292–301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25316001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ponsioen CY, Chapman RW, Chazouillères O, et al.  Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process. Hepatology. 2016;63:1357–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26418478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abraham SC, Kamath PS, Eghtesad B, Demetris AJ, Krasinskas AM. Liver transplantation in precirrhotic biliary tract disease: portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Am J Surg Pathol. 2006;30:1454–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17063088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology. 2011;54:1842–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3205332</ArticleId>
            <ArticleId IdType="pubmed">21793028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boonstra K, van Erpecum KJ, van Nieuwkerk KM, et al.  Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2270–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22407885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khaderi SA, Sussman NL. Screening for malignancy in primary sclerosing cholangitis (PSC) Curr Gastroenterol Rep. 2015;17:17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25786901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buckles DC, Lindor KD, Larusso NF, Petrovic LM, Gores GJ. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol. 2002;97:1138–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12014717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol. 2008;48:598–605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18222013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasiacarcinoma sequence. Am J Surg Pathol. 2007;31:907–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17527079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2013;11(1):13–21.e1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3596004</ArticleId>
            <ArticleId IdType="pubmed">22982100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizvi S, Eaton JE, Gores GJ. Primary sclerosing cholangitis as a premalignant biliary tract disease: surveillance and management. Clin Gastroenterol Hepatol. 2015;13:2152–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4618039</ArticleId>
            <ArticleId IdType="pubmed">26051390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angulo P, Grandison GA, Fong DG, et al.  Bone disease in patients with primary sclerosing cholangitis. Gastroenterology. 2011;140:180–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3043598</ArticleId>
            <ArticleId IdType="pubmed">20955707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergquist A, Montgomery SM, Bahmanyar S, et al.  Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2008;6:939–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18674735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karlsen TH, Franke A, Melum E, et al.  Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010;138:1102–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19944697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melum E, Franke A, Schramm C, et al.  Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet. 2011;43:17–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4354850</ArticleId>
            <ArticleId IdType="pubmed">21151127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu JZ, Hov JR, Folseraas T, et al.  Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet. 2013;45:670–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3667736</ArticleId>
            <ArticleId IdType="pubmed">23603763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Næss S, Lie BA, Melum E, et al.  Refinement of the MHC risk map in a Scandinavian primary sclerosing cholangitis population. PLoS One. 2014;9(12):e114486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4270690</ArticleId>
            <ArticleId IdType="pubmed">25521205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liaskou E, Jeffery LE, Trivedi PJ, et al.  Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis. Gastroenterology. 2014;147(1):221–232.e7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4961260</ArticleId>
            <ArticleId IdType="pubmed">24726754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sebode M, Peiseler M, Franke B, et al.  Reduced FOXP3(+) regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms. J Hepatol. 2014;60:1010–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24412607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Björnsson E, Chari S, Silveira M, et al.  Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther. 2011;18:198–205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20228674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersen IM, Tengesdal G, Lie BA, Boberg KM, Karlsen TH, Hov JR. Effects of coffee consumption, smoking, and hormones on risk for primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2014;12:1019–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24076415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lammert C, Juran BD, Schlicht E, et al.  Reduced coffee consumption among individuals with primary sclerosing cholangitis but not primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2014;12:1562–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4101072</ArticleId>
            <ArticleId IdType="pubmed">24440215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eaton JE, Juran BD, Atkinson EJ, et al.  A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41:980–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4402146</ArticleId>
            <ArticleId IdType="pubmed">25783671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mueller T, Beutler C, Picó AH, et al.  Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver Int. 2011;31:1574–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22093333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haruta I, Kikuchi K, Hashimoto E, et al.  Long-term bacterial exposure can trigger nonsuppurative destructive cholangitis associated with multifocal epithelial inflammation. Lab Invest. 2010;90:577–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20142809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rausch P, Rehman A, Künzel S, et al.  Colonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (Secretor) genotype. Proc Natl Acad Sci U S A. 2011;108:19030–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3223430</ArticleId>
            <ArticleId IdType="pubmed">22068912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Folseraas T, Melum E, Rausch P, et al.  Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol. 2012;57:366–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3399030</ArticleId>
            <ArticleId IdType="pubmed">22521342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet. 2002;359:150–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11809275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eksteen B, Mora JR, Haughton EL, et al.  Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells. Gastroenterology. 2009;137:320–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3201985</ArticleId>
            <ArticleId IdType="pubmed">19233184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta A, Bowlus CL. Primary sclerosing cholangitis: etiopathogenesis and clinical management. Front Biosci (Elite Ed) 2012;4:1683–705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22201985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eksteen B, Grant AJ, Miles A, et al.  Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med. 2004;200:1511–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2211943</ArticleId>
            <ArticleId IdType="pubmed">15557349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Hara SP, Tabibian JH, Splinter PL, LaRusso NF. The dynamic biliary epithelia: molecules, pathways, and disease. J Hepatol. 2013;58:575–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3831345</ArticleId>
            <ArticleId IdType="pubmed">23085249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Hara SP, Splinter PL, Trussoni CE, Gajdos GB, Lineswala PN, LaRusso NF. Cholangiocyte N-Ras protein mediates lipopolysaccharide-induced interleukin 6 secretion and proliferation. J Biol Chem. 2011;286:30352–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3162394</ArticleId>
            <ArticleId IdType="pubmed">21757746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabibian JH, O’Hara SP, Splinter PL, Trussoni CE, LaRusso NF. Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis. Hepatology. 2014;59:2263–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4167827</ArticleId>
            <ArticleId IdType="pubmed">24390753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest. 2013;123:966–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3582125</ArticleId>
            <ArticleId IdType="pubmed">23454759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acosta JC, O’Loghlen A, Banito A, et al.  Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell. 2008;133:1006–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18555777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coppé JP, Patil CK, Rodier F, et al.  Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6(12):2853–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2592359</ArticleId>
            <ArticleId IdType="pubmed">19053174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuilman T, Michaloglou C, Vredeveld LC, et al.  Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell. 2008;133:1019–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18555778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pollheimer MJ, Trauner M, Fickert P. Will we ever model PSC? — “it’s hard to be a PSC model!”. Clin Res Hepatol Gastroenterol. 2011;35:792–804.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21703962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19501929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindor KD. Ursodiol for primary sclerosing cholangitis. N Engl J Med. 1997;336:691–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9041099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindor KD, Kowdley KV, Luketic VA, et al.  High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50:808–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2758780</ArticleId>
            <ArticleId IdType="pubmed">19585548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindor KD, Kowdley KV, Harrison ME. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol. 2015;110:646–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25869391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiorucci S, Rizzo G, Antonelli E, et al.  A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther. 2005;314:584–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15860571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakken KE, Nygård S, Haaland T, et al.  Multiple inflammatory-, tissue remodelling- and fibrosis genes are differentially transcribed in the livers of Abcb4 (−/−) mice harbouring chronic cholangitis. Scand J Gastroenterol. 2007;42:1245–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17852852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halilbasic E, Fiorotto R, Fickert P, et al.  Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice. Hepatology. 2009;49:1972–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3569724</ArticleId>
            <ArticleId IdType="pubmed">19475687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miethke AG, Zhang W, Simmons J, et al.  Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice. Hepatology. 2016;63:512–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4713368</ArticleId>
            <ArticleId IdType="pubmed">26172874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabibian JH, Weeding E, Jorgensen RA, et al.  Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis — a pilot study. Aliment Pharmacol Ther. 2013;37:604–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23384404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darwish Murad S, Kim WR, Harnois DM, et al.  Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143(1):88–98.e3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3846443</ArticleId>
            <ArticleId IdType="pubmed">22504095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fosby B, Karlsen TH, Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol. 2012;18:1–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3251800</ArticleId>
            <ArticleId IdType="pubmed">22228965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alabraba E, Nightingale P, Gunson B, et al.  A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl. 2009;15:330–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19243003</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
